ReviewEndocrine2004
Diabetic cardiomyopathy: do women differ from men?
Review in Endocrine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Metabolic effects of interventions to increase exercise in adults with type 2 diabetes.Diabetologia · 2007Pooled it
- Preclinical evidence and possible mechanisms of cardioprotective effects of resveratrol in diabetic cardiomyopathy: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2024Review
- A study on the global burden of non-melanoma skin cancer from 1990 to 2019.Archives of medical science : AMS · 2024Article
- Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics.Journal of molecular cell biology · 2022Review
- Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years.BMC cancer · 2022Article
- Hyperglycemic memory in diabetic cardiomyopathy.Frontiers of medicine · 2022Review
- The Role of Estrogens and Vitamin D in Cardiomyocyte Protection: A Female Perspective.Biomolecules · 2021Review
- Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications.Physiological reviews · 2021Review
- C-Peptide as a Therapy for Type 1 Diabetes Mellitus.Biomedicines · 2021Review
- Women With Diabetes Are at Increased Relative Risk of Heart Failure Compared to Men: Insights From UK Biobank.Frontiers in cardiovascular medicine · 2021Article
- Melatonin Ameliorates MI-Induced Cardiac Remodeling and Apoptosis through a JNK/p53-Dependent Mechanism in Diabetes Mellitus.Oxidative medicine and cellular longevity · 2020Article
- Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.Cardiovascular diabetology · 2017Article
- Estrogen receptor alpha activation enhances mitochondrial function and systemic metabolism in high-fat-fed ovariectomized mice.Physiological reports · 2016Article
- Sexual dimorphism in myocardial acylcarnitine and triglyceride metabolism.Biology of sex differences · 2016Article
- Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy.Biochimica et biophysica acta · 2015Review
- Metabolic dysfunction in diabetic cardiomyopathy.Heart failure reviews · 2014Review
- Article
- Association of plasma angiotensin-(1-7) level and left ventricular function in patients with type 2 diabetes mellitus.PloS one · 2013Article
- Sex differences in mesenteric endothelial function of streptozotocin-induced diabetic rats: a shift in the relative importance of EDRFs.American journal of physiology. Heart and circulatory physiology · 2012Article
- Sex-specific outcomes of diabetic patients with acute myocardial infarction who have undergone percutaneous coronary intervention: a register linkage study.Cardiovascular diabetology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although many aspects of cardiovascular disease are similar between women and men, it is becoming increasingly obvious that there are significant differences as well. Premenopausal women usually have a lower risk of cardiovascular diseases than age-matched men and postmenopausal women. However, the "female advantage" disappears once women are afflicted with diabetes mellitus. Heart diseases are twice as common in diabetic men and five times as common in diabetic women. It is believed that differences in sex hormones and intrinsic myocardial and endothelial functions between men and women may be responsible for this female "advantage" and "disadvantage" in normal and diabetic conditions. Most experimental and clinical studies on diabetes only included male subjects and failed to address this important gender difference in diabetic heart complications. Although female hearts may be better tolerated to stress (such as ischemia) insults than their male counterparts, female sex hormone such as estrogen may interact with certain risk factors under diabetes which may compromise the overall cardiac function. The benefit versus risk of estrogen replacement therapy on cardiac function and overall cardiovascular health in diabetes remains controversial. This review will focus on gender-related difference in diabetic heart complication--diabetic cardiomyopathy--and if gender differences in intrinsic myocardial contraction, polyol pathway metabolism, and advanced glycation endproduct formation and other neuroendocrinal regulatory mechanisms to the heart may contribute to disparity in diabetic cardiomyopathy between men and women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.